Use of ruxolitinib in patients with myelofibrosis can cause inhibition of the JAK-STAT signaling, thus leading to depressed T helper cell type 1 response and a reduction of multiple cytokine production including IFN-γ and TNF-α. The gene discussed is SOAT1; the disease is myelofibrosis.